NO2018041I1 - - Google Patents

Info

Publication number
NO2018041I1
NO2018041I1 NO2018041C NO2018041C NO2018041I1 NO 2018041 I1 NO2018041 I1 NO 2018041I1 NO 2018041 C NO2018041 C NO 2018041C NO 2018041 C NO2018041 C NO 2018041C NO 2018041 I1 NO2018041 I1 NO 2018041I1
Authority
NO
Norway
Application number
NO2018041C
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2018041(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2018041I1 publication Critical patent/NO2018041I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
NO2018041C 2008-08-22 2018-12-14 NO2018041I1 (https=)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US9109708P 2008-08-22 2008-08-22
US9112508P 2008-08-22 2008-08-22
US9111008P 2008-08-22 2008-08-22
US16589409P 2009-04-01 2009-04-01
US16589909P 2009-04-01 2009-04-01
US16590509P 2009-04-02 2009-04-02
PCT/US2009/054706 WO2010022383A2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
EP09748557.7A EP2365988B2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Publications (1)

Publication Number Publication Date
NO2018041I1 true NO2018041I1 (https=) 2018-12-14

Family

ID=41707686

Family Applications (2)

Application Number Title Priority Date Filing Date
NO2018004C NO2018004I1 (no) 2008-08-22 2018-01-17 patiromersorbitekskalsium og et hvert salt og derivat derav
NO2018041C NO2018041I1 (https=) 2008-08-22 2018-12-14

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO2018004C NO2018004I1 (no) 2008-08-22 2018-01-17 patiromersorbitekskalsium og et hvert salt og derivat derav

Country Status (26)

Country Link
US (4) US20110236340A1 (https=)
EP (4) EP4201408B1 (https=)
JP (7) JP5756403B2 (https=)
KR (5) KR102178208B1 (https=)
CN (2) CN102202670B (https=)
AU (1) AU2009282721B2 (https=)
BR (1) BRPI0917853C1 (https=)
CA (1) CA2735058C (https=)
CY (3) CY2018002I1 (https=)
DE (1) DE112009002063T5 (https=)
DK (3) DK2957286T3 (https=)
ES (4) ES2699494T3 (https=)
FI (1) FI3431094T3 (https=)
GB (4) GB2495427B (https=)
HR (4) HRP20230091T1 (https=)
HU (4) HUE025934T2 (https=)
LT (4) LT3431094T (https=)
LU (1) LUC00094I2 (https=)
MX (3) MX389664B (https=)
NL (1) NL300962I2 (https=)
NO (2) NO2018004I1 (https=)
PL (4) PL2365988T5 (https=)
PT (3) PT2365988E (https=)
SI (2) SI3431094T1 (https=)
SM (2) SMT201800660T1 (https=)
WO (1) WO2010022383A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574716B2 (en) * 2006-01-23 2013-11-05 Hitachi Chemical Co., Ltd. Ionic polymer devices and methods of fabricating the same
PT2365988E (pt) 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
KR101839038B1 (ko) * 2010-03-20 2018-03-16 리립사, 인크. 폴리플루오로아크릴레이트 입자를 제조하기 위한 연속식 방법
SI2673237T2 (sl) 2011-02-11 2025-12-31 Zs Pharma, Inc Uporaba cirkonijevega silikata v zdravljenju hiperkalemije
ES2895909T3 (es) 2011-06-27 2022-02-23 Vifor Pharma Tech Ltd Procedimiento para la conversión de un éster polimérico a un ácido polimérico
RU2619108C2 (ru) 2011-06-27 2017-05-12 Релипса, Инк. Фторирование эфиров акриловой кислоты и их производных
CA2879425A1 (en) * 2012-07-19 2014-01-23 Relypsa, Inc. Compositions comprising crosslinked cation-binding polymers
WO2014023826A1 (en) * 2012-08-09 2014-02-13 Dsm Ip Assets B.V. Process for drying polymeric materials
KR20210005314A (ko) * 2012-10-08 2021-01-13 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
BR112015025438B1 (pt) 2013-04-05 2022-06-07 Zs Pharma, Inc Uso de um silicato de zircônio
EP3236940B1 (en) * 2014-12-23 2020-02-05 Ardelyx, Inc. Compositions and methods for treating hyperkalemia
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
WO2019220450A1 (en) 2018-05-16 2019-11-21 Solara Active Pharma Sciences Limited Process for preparation of patiromer
BR112021017791A2 (pt) * 2019-03-13 2022-02-01 Astrazeneca Ab Agentes de ligação ao potássio para uso em pacientes em hemodiálise
WO2021097012A1 (en) * 2019-11-14 2021-05-20 Relypsa, Inc. One step synthesis for alkyl 2-fluoroacrylates
WO2021191876A1 (en) 2020-03-27 2021-09-30 Vifor (International) Ltd. Synthesis of methyl 2-fluoroacrylate
CN116323717A (zh) * 2021-09-13 2023-06-23 中美华世通生物医药科技(武汉)股份有限公司 治疗高钾血症的聚合物药物及其制备方法
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN114369729B (zh) * 2021-12-28 2023-11-03 江苏容汇通用锂业股份有限公司 一种利用锂矿渣进行浸出液除钾的工艺
CN114394918B (zh) * 2022-01-19 2023-10-20 罗长青 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
NL137053C (https=) 1967-01-30
FR2171934B1 (https=) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
DE2846187A1 (de) 1978-10-24 1980-05-08 Bayer Ag Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) † 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
EP0565086B1 (en) 1992-04-10 1996-12-27 Mitsubishi Chemical Corporation Method for producing a spherical acrylonitrile crosslinked copolymer
ATE168707T1 (de) * 1992-08-20 1998-08-15 Du Pont Vernetzte polymerische ammoniumsalze
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) * 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
KR100440544B1 (ko) * 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
DE19951116A1 (de) 1999-10-23 2001-04-26 Bosch Gmbh Robert Relais, insbesondere für eine Startvorrichtung
DE19962935A1 (de) † 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen
CA2396915A1 (en) * 2000-01-14 2001-07-19 Otsuka Pharmaceutical Factory, Inc. Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
JP4873824B2 (ja) * 2000-08-01 2012-02-08 オリザ油化株式会社 糖質吸収阻害剤およびその製造方法
AU2002232955A1 (en) * 2000-11-20 2002-05-27 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
CA2516457C (en) * 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
BRPI0509365B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
BRPI0616603A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
WO2007041569A1 (en) * 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
AU2008292907A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
PT2365988E (pt) 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia

Also Published As

Publication number Publication date
PT3431094T (pt) 2023-03-03
KR101928973B1 (ko) 2018-12-13
EP4201408B1 (en) 2025-06-25
LUC00094I2 (https=) 2020-01-23
CY2018002I1 (el) 2019-07-10
GB201222749D0 (en) 2013-01-30
KR102150184B1 (ko) 2020-08-31
PT2957286T (pt) 2018-11-30
AU2009282721B2 (en) 2015-10-29
KR20180133561A (ko) 2018-12-14
JP6633583B2 (ja) 2020-01-22
KR102300471B1 (ko) 2021-09-30
GB201222750D0 (en) 2013-01-30
US20220000906A1 (en) 2022-01-06
DK2365988T4 (da) 2019-10-07
BRPI0917853B1 (pt) 2020-04-07
EP2957286A1 (en) 2015-12-23
JP2019065030A (ja) 2019-04-25
KR20200029614A (ko) 2020-03-18
KR102178208B1 (ko) 2020-11-12
CA2735058C (en) 2021-01-26
CN103919792A (zh) 2014-07-16
SMT201800660T1 (it) 2019-01-11
DK2957286T3 (en) 2018-12-17
WO2010022383A2 (en) 2010-02-25
MX389664B (es) 2025-03-20
US20170165292A1 (en) 2017-06-15
GB2495426A (en) 2013-04-10
EP4201408C0 (en) 2025-06-25
HK1184675A1 (en) 2014-01-30
EP4201408A1 (en) 2023-06-28
ES2699494T3 (es) 2019-02-11
HUE025934T2 (en) 2016-05-30
HUE071829T2 (hu) 2025-09-28
JP5756403B2 (ja) 2015-07-29
ES2545887T3 (es) 2015-09-16
WO2010022383A3 (en) 2010-09-23
LTPA2018004I1 (lt) 2018-02-12
CN103919792B (zh) 2018-03-09
MX364398B (es) 2019-04-24
NL300962I2 (nl) 2020-06-02
CN102202670A (zh) 2011-09-28
HUS1900003I1 (hu) 2019-02-28
JP6890116B2 (ja) 2021-06-18
CY2019002I2 (el) 2020-05-29
GB201104561D0 (en) 2011-05-04
AU2009282721A1 (en) 2010-02-25
CY2019002I1 (el) 2020-05-29
LUC00094I1 (https=) 2018-12-19
HRP20150955T1 (hr) 2015-10-09
GB2495428A (en) 2013-04-10
JP5883471B2 (ja) 2016-03-15
SMT201500207T1 (it) 2015-10-30
SI2957286T1 (sl) 2018-12-31
FI3431094T3 (fi) 2023-03-20
JP6232468B2 (ja) 2017-11-15
ES2545887T5 (es) 2020-02-17
KR20200128600A (ko) 2020-11-13
GB2475657B (en) 2013-05-29
PL3431094T3 (pl) 2023-04-24
DE112009002063T5 (de) 2012-01-12
JP2014144977A (ja) 2014-08-14
EP2365988B1 (en) 2015-07-22
JP2014144978A (ja) 2014-08-14
GB2475657A (en) 2011-05-25
HRP20250774T1 (hr) 2025-08-29
EP3431094B1 (en) 2022-12-07
SI3431094T1 (sl) 2023-04-28
GB2495427A (en) 2013-04-10
JP2012500806A (ja) 2012-01-12
PL4201408T3 (pl) 2025-09-22
LT2957286T (lt) 2018-12-10
DK2365988T3 (en) 2015-10-26
US20110236340A1 (en) 2011-09-29
HUE061320T2 (hu) 2023-06-28
US20200289550A1 (en) 2020-09-17
NO2018004I1 (no) 2018-01-17
PL2957286T3 (pl) 2019-03-29
GB201222752D0 (en) 2013-01-30
BRPI0917853B8 (pt) 2020-04-22
ES3034535T3 (en) 2025-08-19
KR20180014845A (ko) 2018-02-09
KR20110063647A (ko) 2011-06-13
HRP20230091T1 (hr) 2023-03-17
CN102202670B (zh) 2014-04-30
DK3431094T3 (da) 2023-02-20
PL2365988T5 (pl) 2019-11-29
BRPI0917853A2 (pt) 2015-11-24
GB2495427B (en) 2013-08-07
JP2016145256A (ja) 2016-08-12
JP2020172537A (ja) 2020-10-22
LTC2957286I2 (lt) 2019-11-25
EP2365988A2 (en) 2011-09-21
CA2735058A1 (en) 2010-02-25
LT3431094T (lt) 2023-02-27
KR101825113B1 (ko) 2018-02-02
JP2017218454A (ja) 2017-12-14
EP2365988B2 (en) 2019-07-03
HRP20181961T1 (hr) 2019-02-08
LTPA2018016I1 (lt) 2019-01-10
CY1120930T1 (el) 2020-05-29
NL300962I1 (nl) 2018-12-28
PL2365988T3 (pl) 2015-12-31
PT2365988E (pt) 2015-10-22
BRPI0917853C1 (pt) 2021-05-25
EP2957286B1 (en) 2018-11-21
ES2939021T3 (es) 2023-04-18
EP3431094A1 (en) 2019-01-23
MX2011001893A (es) 2011-09-27

Similar Documents

Publication Publication Date Title
BRPI0909040A2 (https=)
BRPI0917573A2 (https=)
BRPI0908549B8 (https=)
BRPI0918697A2 (https=)
BRPI0917525A2 (https=)
BRPI0920750A2 (https=)
BRPI0919470A2 (https=)
BRPI0907698A2 (https=)
BRPI0917618A8 (https=)
BRPI0922455A2 (https=)
BRPI0923734A2 (https=)
BRPI0912727A2 (https=)
BRPI0922669A2 (https=)
BRPI0908285A2 (https=)
BRPI0910485A2 (https=)
BRPI0914750A2 (https=)
BRPI0919811A2 (https=)
BRPI0915616A2 (https=)
BRPI0908120A2 (https=)
BRPI0912462A2 (https=)
BRPI0904541A8 (https=)
BRPI0920914A2 (https=)
BRPI0922550A2 (https=)
BRPI0916284A2 (https=)
BRPI0911617A2 (https=)